Standard treatments for CF, such as dornase alfa (a recombinant DNAse) and tobramycin inhalations, were approved in 2012 [3], and the CFTR gene variant test is now available in the Japanese Health Insurance system [4]. This evidence concerns the gene CFTR and cystic fibrosis.